{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:40:02Z","timestamp":1762508402774,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Safe and effective vaccines provide the first hope for mitigating the devastating health and economic impacts resulting from coronavirus disease 2019 (COVID-19) and related public health orders. Recent case reports of reactions to COVID-19 vaccines have raised questions about their safety for use in individuals with allergies and those who are immunocompromised. In this document, we aim to address these concerns and provide guidance for allergists\/immunologists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Scoping review of the literature regarding COVID-19 vaccination, adverse or allergic reactions, and immunocompromise from PubMed over the term of December 2020 to present date. We filtered our search with the terms \u201chuman\u201d and \u201cEnglish\u201d and limited the search to the relevant subject age range with the term \u201cadult.\u201d Reports resulting from these searches and relevant references cited in those reports were reviewed and cited on the basis of their relevance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Assessment by an allergist is warranted in any individual with a suspected allergy to a COVID-19 vaccine or any of its components. Assessment by an allergist is NOT required for individuals with a history of unrelated allergies, including to allergies to foods, drugs, insect venom or environmental allergens. COVID-19 vaccines should be offered to immunocompromised patients if the benefit is deemed to outweigh any potential risks of vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretation<\/jats:title>\n                <jats:p>This review provides the first Canadian guidance regarding assessment of an adolescent and adult with a suspected allergy to one of the COVID-19 vaccines currently available, or any of their known allergenic components, and for patients who are immunocompromised who require vaccination for COVID-19. As information is updated this guidance will be updated accordingly.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-021-00529-2","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:04:18Z","timestamp":1615806258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["COVID-19 vaccine testing &amp; administration guidance for allergists\/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI)"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-4840","authenticated-orcid":false,"given":"Timothy K.","family":"Vander Leek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Derfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne K.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia E. M.","family":"Upton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissa M.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"529_CR1","unstructured":"Vaccine safety, concerns and possible side effects\u2014Canada.ca [Internet]. 2021. https:\/\/www.canada.ca\/en\/public-health\/services\/vaccination-children\/safety-concerns-side-effects.html. Accessed 3 Jan 2021."},{"key":"529_CR2","unstructured":"Anaphylaxis and other Acute Reactions following Vaccination: Canadian Immunization Guide\u2014Canada.ca [Internet]. 2020. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-2-vaccine-safety\/page-4-early-vaccine-reactions-including-anaphylaxis.html. Accessed 24 Dec 2020."},{"issue":"2","key":"529_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","volume":"141","author":"MM McNeil","year":"2018","unstructured":"McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463\u201372.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"529_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/pai.12132","volume":"25","author":"J-C Caubet","year":"2014","unstructured":"Caubet J-C, Rudzeviciene O, Gomes E, Terreehorst I, Brockow K, Eigenmann PA. Managing a child with possible allergy to vaccine. Pediatr Allergy Immunol. 2014;25(4):394\u2013403.","journal-title":"Pediatr Allergy Immunol"},{"key":"529_CR5","doi-asserted-by":"crossref","unstructured":"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine\u2014United States, December 14\u201323, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2021. https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7002e1.htm?s_cid=mm7002e1_w. Accessed 7 Jan 2021.","DOI":"10.15585\/mmwr.mm7002e1"},{"key":"529_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2035343","author":"MC Castells","year":"2020","unstructured":"Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines Longo DL, editor. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMra2035343.","journal-title":"N Engl J Med."},{"issue":"6","key":"529_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaci.2012.07.019","volume":"130","author":"I Rouleau","year":"2012","unstructured":"Rouleau I, De Serres G, Drolet JP, Banerjee D, Lemire C, Moore A, et al. Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. J Allergy Clin Immunol. 2012;130(6):1423\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"529_CR8","unstructured":"Coronavirus (COVID-19) Vaccinations\u2014Statistics and Research\u2014Our World in Data [Internet]. 2021. https:\/\/ourworldindata.org\/covid-vaccinations. Accessed 10 Jan 2021."},{"key":"529_CR9","unstructured":"Recommendations on the use of COVID-19 vaccines\u2014Canada.ca [Internet]. 2020. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines.html. Accessed 24 Dec 2020."},{"key":"529_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.011","author":"Z-H Zhou","year":"2020","unstructured":"Zhou Z-H, Stone CA, Jakubovic B, Phillips EJ, Sussman G, Park J, et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2020. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.011.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"529_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","volume":"7","author":"CA Stone","year":"2019","unstructured":"Stone CA, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533-1540.e8.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"529_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","volume":"46","author":"E Wenande","year":"2016","unstructured":"Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907\u201322.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"529_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13223-016-0172-7","volume":"12","author":"K Wylon","year":"2016","unstructured":"Wylon K, D\u00f6lle S, Worm M. Polyethylene glycol as a cause of anaphylaxis. Allergy Asthma Clin Immunol. 2016;12(1):67.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"529_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.029","author":"P Sellaturay","year":"2020","unstructured":"Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2020. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.029.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"7","key":"529_CR15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.jaip.2019.05.058","volume":"7","author":"G Calogiuri","year":"2019","unstructured":"Calogiuri G, Foti C, Nettis E, Di Leo E, Macchia L, Vacca A. Polyethylene glycols and polysorbates: Two still neglected ingredients causing true IgE-mediated reactions. J Allergy Clin Immunol Pract. 2019;7(7):2509\u201310.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"529_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.12.047","author":"A Banerji","year":"2020","unstructured":"Banerji A, Wickner PG, Saff R, Stone CA, Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and approach. J Allergy Clin Immunol Pract. 2020. https:\/\/doi.org\/10.1016\/j.jaip.2020.12.047.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"529_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jaip.2016.03.017","volume":"4","author":"D Spoerl","year":"2016","unstructured":"Spoerl D, Jandus P, Harr T. Pitfalls and peculiarities in chlorhexidine allergy. J Allergy Clin Immunol Pract. 2016;4(5):991\u20132.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"529_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","volume":"130","author":"JM Kelso","year":"2012","unstructured":"Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25\u201343.","journal-title":"J Allergy Clin Immunol"},{"key":"529_CR19","unstructured":"Pfizer-BioNTech COVID-19 Vaccine (tozinameran) | COVID-19 vaccines and treatments portal [Internet]. 2020. https:\/\/covid-vaccine.canada.ca\/pfizer-biontech-covid-19-vaccine\/product-details. Accessed 24 Dec 2020."},{"key":"529_CR20","unstructured":"Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2) | COVID-19 vaccines and treatments portal [Internet]. 2020. https:\/\/covid-vaccine.canada.ca\/moderna-covid-19-vaccine\/product-details. Accessed 24 Dec 2020."},{"key":"529_CR21","unstructured":"COVID-19: the green book, chapter 14a\u2014GOV.UK [Internet]. 2021. https:\/\/www.gov.uk\/government\/publications\/covid-19-the-green-book-chapter-14a. Accessed 3 Jan 2021."},{"key":"529_CR22","unstructured":"ESID\u2014European Society for Immunodeficiencies [Internet]. 2021. https:\/\/esid.org\/COVID-19\/ESID-COVID-19-Statement. Accessed 3 Jan 2021."},{"key":"529_CR23","unstructured":"EULAR | EULAR View-points on SARS-CoV-2 vaccination in patients with RMDs [Internet]. 2021. https:\/\/www.eular.org\/eular_sars_cov_2_vaccination_rmd_patients.cfm. Accessed 3 Jan 2021."}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13223-021-00529-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T09:20:28Z","timestamp":1617268828000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00529-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00529-2","relation":{},"ISSN":["1710-1492"],"issn-type":[{"type":"electronic","value":"1710-1492"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TV has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer (EpiPen). EC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma; and is a member of the healthcare advisory board for Food Allergy Canada. LC has been on advisory boards for Abbvie, ALK, Bausch & Lombe, GSK and Sanofi. She has provided speaking engagements for Astra Zeneca, GSK and Sanofi. AE, within the past 12\u00a0months, has participated in advisory boards for ALK Abello, AstraZeneca, Aralez, Bausch Health, LEO Pharma, Merck, Novartis, and Pfizer, has been a speaker for ALK Abello, Aralez, AstraZeneca, Medexus, and Mylan. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, and Regeneron. She has also served as an independent consultant to Bayer LLC and Regeneron. BD has received a research grant from CSL Behring and personal fees from SOBI. JU reports prior consulting for Pfizer (EpiPen), not related to the current work. EA serves on the healthcare advisory board of Food Allergy Canada and receives moderator\/speaker fees from GSK, Novartis, and AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}